由于脓疱溃疡症（PG）是一种罕见的中性粒细胞皮肤病，对该疾病的流行病学和临床数据相对较少。本单中心回顾性研究旨在评估2014年至2022年期间大学医院内PG患者的临床特征、潜在系统性相关性以及治疗方法。已知PG最常影响下肢，但也应考虑到皮肤外的受累情况。PG通常伴随着与该疾病具有相似炎症发病机制的多种合并症。不同研究中PG相关合并症的患病率不同，在本研究中最常见的是关节炎和实体器官恶性肿瘤。包括糖尿病、高血压和外周血管疾病在内的非PG相关合并症可能不利于伤口愈合并限制治疗选择，因此对PG患者的整体治疗十分重要。与文献一致，PG的主要治疗方法是全身性皮质类固醇和环孢素。然而，生物制剂在治疗耐药患者中的应用日益成为文献中的重要问题。抗肿瘤坏死因子（anti-TNF）是最常用的生物治疗方法，这些药物似乎为PG的治疗开辟了新的途径。在本研究中，相对较高百分比（23.3%）的患者接受了抗-TNF治疗，其中以英夫西妥单抗（infliximab）最常见（87.5%）。随访期内我们观察到46.7%的患者复发，相比使用单一药物的患者，使用多种全身性治疗的患者复发率更高（64.7% vs 23.1%，P < 0.05）。总之，我们强调早期诊断和治疗以及考虑患者合并症在预防并发症中的重要性，而生物治疗在治疗耐药患者中似乎特别有前景。

Since pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis, epidemiological and clinical data on the disease are scarce. In this single-center retrospective study, we aim to evaluate the clinical characteristics, underlying systemic associations and treatment modalities in patients with PG in a university hospital between 2014 and 2022. It is known that PG most commonly affects the lower extremities, but extracutaneous involvement should also be kept in mind. PG is usually associated with various comorbidities that share a similar inflammatory pathogenesis with the disease. The prevalence of PG-related comorbidities varies in different studies, arthritis and solid organ malignancies were observed most frequently in the current study. Non-PG-related comorbidities including diabetes mellitus, hypertension and peripheral vascular disease can adversely affect wound healing and limit treatment options; therefore, a holistic approach to patients with PG is crucial. Consistent with literature, the mainstay of treatment for PG is systemic corticosteroids and cyclosporine. However, the implementation of biologic agents in treatment-resistant patients is an increasingly important issue in the literature. Antitumor necrosis factors (anti-TNFs) are the most commonly preferred biological therapies, and these agents seem to have paved the way for a paradigm shift in the treatment of PG. In the present study, a relatively high per cent of (23.3%) patients treated with anti-TNFs, most commonly infliximab (87.5%). Recurrence was observed in 46.7% of our patients in the follow-up period and the relapse rate was found to be higher in patients using multiple systemic agents compared to those using single agents (64.7% vs 23.1%, P < .05). In conclusion, we emphasize that early diagnosis and treatment by considering the patient's comorbidities are important in preventing complications, and biologic treatments seem particularly promising in treatment-resistant patients.